Trevi Therapeutics completed a $162 million stock offering, extending its cash runway into 2030 to support ongoing development of Haduvio for chronic cough related to IPF, non-IPF ILD, and refractory chronic cough. The company plans to initiate multiple clinical trials in 2026, including Phase 3 trials for IPF-related chronic cough and Phase 2b trials for RCC and non-IPF ILD-related cough. With recent FDA alignment and a new European patent, Trevi is positioned to advance toward potential FDA approval. Financially, the company reported a net loss of $13.2 million for Q1 2026, with increased R&D and administrative expenses reflecting clinical progress.
Orange announced its intention to issue new perpetual hybrid bonds with a fixed adjustable interest rate and to launch a buyback offer for certain existing hybrid bonds. The new bonds are expected to be rated BBB-/Baa3/BBB- and traded on Euronext Par...
Orange announced its intention to issue new Euro-denominated hybrid notes with a 7-year non-call period and fixed-to-reset rates, expected to be rated BBB-/Baa3/BBB-. Simultaneously, the company is launching a tender offer to repurchase some of its o...
Bavarian Nordic A/S has repurchased 146,973 shares at an average price of DKK 181.75, totaling DKK 26.7 million, as part of its share buy-back program launched on June 2, 2026. The program allows the company to buy back shares up to DKK 150 million b...
Bavarian Nordic A/S announced it repurchased 146,973 shares at an average price of DKK 181.75, totaling DKK 26.7 million, as part of its share buy-back program running from June 2 to July 10, 2026. The company now holds 2,884,957 treasury shares, rep...
Schneider Electric and Hon Hai Technology Group (Foxconn) have announced a strategic collaboration to develop and scale next-generation AI data centers. This partnership combines Foxconn's expertise in AI systems and manufacturing with Schneider Elec...
